SRT1720 Induces Mitochondrial Biogenesis and Rescues Mitochondrial Function after Oxidant Injury in Renal Proximal Tubule Cells
- 1 May 2010
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 333 (2) , 593-601
- https://doi.org/10.1124/jpet.109.161992
Abstract
Mitochondrial biogenesis occurs under basal conditions and is an adaptive response initiated by cells to maintain energetic demands and metabolic homeostasis after injuries targeting mitochondrial function. Identifying pharmacological agents that stimulate mitochondrial biogenesis is a critical step in the development of new therapeutics for the treatment of these injuries and to test the hypothesis that these agents will expedite recovery of cell and organ function after acute organ injuries. In this study, we examined the effects of N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide (SRT1720) on mitochondrial biogenesis and function in primary cultures of renal proximal tubule cells (RPTCs). We also tested the ability of this compound to restore mitochondrial functions after oxidant-induced RPTC injury. SRT1720 (3–10 μM) induced mitochondrial biogenesis in RPTCs within 24 h as determined by elevations in mitochondrial DNA copy number, increased expression of the mitochondrial proteins NADH dehydrogenase 1β subcomplex subunit 8 (NDUFB8) and ATP synthase β, and elevated mitochondrial respiration rates and ATP levels. Induction of mitochondrial biogenesis depended on mammalian sirtuin 1 (SIRT1) deacetylase activity, correlated with deacetylated nuclear peroxisome proliferator-activated receptor coactivator (PGC)-1α, and occurred in the absence of AMP-dependent kinase (AMPK) activation. Finally, SRT1720 treatment accelerated recovery of mitochondrial functions after acute oxidant injury. This study demonstrates that SRT1720 can induce mitochondrial biogenesis through SIRT1 activity and deacetylated PGC-1α, but not AMPK, in RPTCs within 24 h after oxidant injury. The results support further study of mitochondrial biogenesis as a repair process and a pharmacological target in acute organ injuries and disorders plagued by mitochondrial impairment.This publication has 44 references indexed in Scilit:
- Resveratrol induces mitochondrial biogenesis in endothelial cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivoBMC Systems Biology, 2009
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- Specific SIRT1 Activation Mimics Low Energy Levels and Protects against Diet-Induced Metabolic Disorders by Enhancing Fat OxidationPublished by Elsevier ,2008
- The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1αProceedings of the National Academy of Sciences, 2008
- Oxidants and Ca+2 induce PGC-1α degradation through calpainArchives of Biochemistry and Biophysics, 2008
- SirT1 Regulates Energy Metabolism and Response to Caloric Restriction in MicePLOS ONE, 2008
- Thyroid hormone action in mitochondriaJournal of Molecular Endocrinology, 2001
- The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylasesProceedings of the National Academy of Sciences, 2000
- Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediatesProceedings of the National Academy of Sciences, 2000